Renal subcapsular delivery of PGE2 promotes kidney repair by activating endogenous Sox9+ stem cells

Shang Chen,Haoyan Huang,Yue Liu,Chen Wang,Xiaoniao Chen,Yuqiao Chang,Yuhao Li,Zhikun Guo,Zhibo Han,Zhong-Chao Han,Qiang Zhao,Xiang-Mei Chen,Zongjin Li
DOI: https://doi.org/10.1016/j.isci.2021.103243
IF: 5.8
2021-11-01
iScience
Abstract:Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) has recently been recognized to play a role in immune regulation and tissue regeneration. However, the short half-life of PGE<sub>2</sub> limits its clinical application. Improving the delivery of PGE<sub>2</sub> specifically to the target organ with a prolonged release method is highly desirable. Taking advantage of the adequate space and proximity of the renal parenchyma, renal subcapsular delivery allows minimally invasive and effective delivery to the entire kidney. Here, we report that by covalently cross-linking it to a collagen matrix, PGE<sub>2</sub> exhibits an adequate long-term presence in the kidney with extensive intraparenchymal penetration through renal subcapsular delivery and significantly improves kidney function. Sox9 cell lineage tracing with intravital microscopy revealed that PGE<sub>2</sub> could activate the endogenous renal progenitor Sox9<sup>+</sup> cells through the Yap signaling pathway. Our results highlight the prospects of utilizing renal subcapsular-based drug delivery and facilitate new applications of PGE<sub>2</sub>-releasing matrices for regenerative therapy.
multidisciplinary sciences
What problem does this paper attempt to address?